Thrombosis and Meningococcal Infection Rates in Pegcetacoplan Patients With Paroxysmal Nocturnal Hemoglobinuria in the Post-marketing Setting

P838

Jens Panse[1,2], Richard J. Kelly[3], Hisakazu Nishimori[4,5], Regina Horneff[6], Peter Hillmen[7], Uchendu O. Uchendu[7], Stacie Lallier[7], Gloria F. Gerber[8]

[1]Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen, Germany; [2]Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany; [3]St James's University Hospital, Leeds, UK; [4]Okayama University Hospital, Okayama, Japan; [5]Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; [6]Swedish Orphan Biovitrum AB, Stockholm, Sweden; [7]Apellis Pharmaceuticals, Inc., Waltham, MA, USA; [8]Johns Hopkins University School of Medicine, Baltimore, MD, USA

OBJECTIVE

To report the most current real-world rates of thrombosis and meningococcal infections in patients with PNH treated with pegcetacoplan in the post-marketing setting as of November 13, 2023

INTRODUCTION

- Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hematologic disease characterized by complement-mediated hemolysis, aplasia, and thrombosis[1,2]
- Before approval of complement inhibitors, thrombosis was the leading cause of death in patients with PNH[1]
- Complement inhibitors have subsequently decreased thrombosis rates (**Table 1**)[3]
  - In patients who received the C5 inhibitor (C5i) eculizumab in clinical trials, the thrombosis rate with eculizumab was 1.07 events/100 patient-years (PY)[4]
  - The thrombosis rate with the C5i ravulizumab was similar (1.21 events/100 PY)[5]
  - In clinical trials of pegcetacoplan, the first C3-targeted therapy for PNH, the thrombosis rate was 1.22 events/100 PY[6]
  - In a registry study of patients with PNH receiving C5is in the United Kingdom (May 2002 to July 2022), the thrombosis rate was 0.73 events/100 PY[7]

Table 1. Thrombosis rates previously reported in patients with PNH

Setting, complement inhibitor (number of patients)	Thrombosis rate, events/100 PY	Thrombotic events, n	Cumulative exposure, y
Clinical trials			
Eculizumab (N=195)[4]			
Before eculizumab	7.37	124	1683
With eculizumab	1.07	3	281
Ravulizumab (N = 434)[5]	1.21	8	662
Pegcetacoplan (N = 170)[6,a]	1.22	5	409
Registry study in the United Kingdom[7]			
Eculizumab or ravulizumab (N = 509)	0.73	23	3130

PNH, paroxysmal nocturnal hemoglobinuria; PY, patient-years.
[a]As of November 13, 2022.

INTRODUCTION*(cont.)*

- Optimal PNH treatment must block complement activity enough to reduce risk of thrombosis without compromising the complement system to an extent that increases the risk of life-threatening infections, especially *Neisseria meningitidis*[8]
- To achieve this fine balance, compliance with the recommended treatment dosing and risk-mitigating strategies for preventing infections are essential

METHODS

- Cumulative pegcetacoplan exposure was calculated in PY
- Post-marketing compliance in the United States was calculated as the proportion of days a patient had the drug in possession divided by the total number of days of follow-up using central pharmacy prescription refill data
- The trial protocols and labels require vaccination against *N meningitidis*, *Streptococcus pneumoniae*, and *Haemophilus influenzae* before pegcetacoplan use; the labels recommend prophylactic antibiotics if pegcetacoplan must be administered prior to vaccination;[9,10] informed consent was obtained before clinical trial participation
- Post-marketing thrombosis (arterial and venous) and meningococcal infection rates were estimated from the total number of events reported in the Apellis/Sobi global safety database, using solicited reports from patient support and market research programs; spontaneous reports from health care providers, consumers, and regulatory agencies; and reports extracted from the literature

RESULTS

- Patients with PNH (N = 578) had experienced a total of 626 PY of pegcetacoplan exposure in the post-marketing setting (in the United States, Europe, and rest of the world) as of November 13, 2023
- Post-marketing compliance in the United States was estimated at 97%
- No meningococcal infections were reported among patients with PNH on pegcetacoplan up to November 13, 2023, across countries in the combined clinical trial and post-marketing contexts (total cumulative exposure of 1127 PY)
- In the post-marketing setting, 2 thrombotic events were reported among patients with PNH on pegcetacoplan up to November 13, 2023, resulting in a thrombosis rate of 0.32 events/100 PY (**Table 2**)
  - In comparison, the reported rate of venous thrombotic events is approximately 0.1–0.2/100 PY in the general population of the United States and Europe[11]

Table 2. Thrombosis rates reported in the real world

Population and setting (number of patients)	Thrombosis rate, events/100 PY	Thrombotic events, n	Cumulative exposure, y
Patients with PNH on pegcetacoplan in thepost-marketing setting in the United States, Europe, and rest of the world[a] (N=578)	0.32	2	626
General population in the United States and Europe[11]	~0.1-0.2		

PNH, paroxysmal nocturnal hemoglobinuria; PY, patient-years.
[a]As of November 13, 2023.

CONCLUSIONS

- ✓ These findings suggest that the thrombosis rate in patients with PNH on pegcetacoplan is low overall and comparable to rates on C5is
- ✓ At the time of data cut, no meningococcal infections had been reported in patients with PNH on pegcetacoplan, suggesting effective risk mitigation strategies
- ✓ A potential confounder is the real-world nature of the data, which may be subject to underreporting; comparison to real-world studies of C5is is limited by the different methods used to ascertain events
- ✓ Continued follow-up is required

REFERENCES **1.** Brodsky RA. *Blood*. 2021;137(10):1304–9. **2.** Risitano AM, et al. *Front Immunol*. 2019;10:1157. **3.** Kelly RJ, et al. *Blood*. 2011;117(25):6786–92. **4.** Hillmen P, et al. *Blood*. 2007;110:4123–8. **5.** Kulasekararaj AG, et al. *Eur J Haematol*. 2022;109:205–14. **6.** Kelly RJ, et al. *Res Pract Thromb Haemost*. Published online April 23, 2024. **7.** Kelly RJ, et al. *Blood*. 2024;143(12):1157–1166. **8.** Rosain J, et al. *J Infect Dis*. 2017;215:1331–8. **9.** Pegcetacoplan. Package insert. Apellis Pharmaceuticals; 2024. **10.** Pegcetacoplan. Summary of product characteristics. Swedish Orphan Biovitrum AB; 2024. **11.** Lutsey PL, Zakai NA. *Nat Rev Cardiol*. 2023;20:248–62.

Disclosures: **JP** reports consultancy and honoraria at Blueprint Medicines, Amgen, F Hoffmann-La Roche, MSD, Bristol Myers Squibb, Alexion, AstraZeneca, Novartis, Pfizer, Gilead, Boehringer Ingelheim, Sobi, and Apellis; and honoraria from Swiss Biopharma. **RJK** has received research funding from Novartis and Sobi; received consultancy fees for Sobi; sat on advisory boards for Alexion, AbbVie, Amgen, Jazz, Novartis, Roche, and Sobi; and received lecture fees from Alexion, Astellas, Amgen, Biologix, Jazz, and Sobi. HN reports consultancy for Kyowa Kirin. **RH** is an employee of Sobi. **PH**, **UOU**, and **SL** are employees of Apellis and hold stock or stock options. **GFG** has participated in advisory boards for Apellis and Alexion; received honorarium for authorship of Merck Manual; and reports employment (spouse) and holding stock/stock options (spouse) at Pfizer.

Acknowledgments: This study was funded by Apellis Pharmaceuticals, Inc. The analysis was funded by Sobi and Apellis Pharmaceuticals, Inc. Medical writing support was provided by Kay Square Scientific and funded by Apellis and Sobi. The authors also thank Dale Zhang for his review and work on the abstract.

Prior presentation: Presented at 1st International PNH Interest Group (IPIG) Conference; May 18–19, 2023; Harrogate, UK. Poster P786 at 28th Annual Congress of the European Hematology Association (EHA) June 8–11, 2023; Frankfurt, Germany.